Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 451-455

  Sumiyoshi, Tomiki ^a,b   Jin, Dai ^a   Jayathilake, Karu ^a   Lee, Myung ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Clozapine; Glycine; Negative symptoms; Schizophrenia; Serine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SERINE;

ADULT; AMINO ACID ANALYSIS; APATHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; MALE; NEGATIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SERINE;

EID: 22344441029     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005237     Document Type: Article

References (35)

1. Altamura CA, Maes M, Dai J, Meltzer HY (1995). Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. European Neuropsychopharmacology 5 (Suppl.) 71-75.
2. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. American Journal of Psychiatry 150, 1731-1733.
3. Andreasen NC (1983). Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
4. APA (1987). DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders (3rd edn, rev). Washington, DC: American Psychiatric Association.
5. Ellenbroek BA, Cools AR (2000). Atypical Antipsychotics. Boston: Birkhauser.
6. Endicott J, Spitzer RL (1978). A diagnostic interview: the schedule for affective disorder and schizophrenia. Archives of General Psychiatry 35, 837-844.
7. Ermilov M, Kremer I, Blanaru M, Bloch B, Neeman G, Javitt D, Heresco-Levy U (2004). Glutamatergic neurotransmission-associated amino acids: Plasma levels and relation to symptoms. International Journal of Neuropsychopharmacology 7 (Suppl. 1), S285-S286.
8. Evins AE, Amico ET, Shih V, Goff DC (1997). Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of Neural Transmission 104, 761-766.
9. Farber NB, Newcomer JW, Olney JW (1999). Glycine agonists: what can they teach us about schizophrenia? Archives of General Psychiatry 56, 13-17.
10. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158, 1367-1377.
11. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999). A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 56, 21-27.
12. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996). D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 153, 1628-1630.
13. Goff DC, Wine L (1997). Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research 27, 157-168.
14. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003). Decreased serum levels of D-serine in patients with schizophrenia : evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Archives of General Psychiatry 60, 572-576.
15. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 55, 165-171.
16. Heresco-Levy U, Javitt DC (2004). Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophrenia Research 66, 89-96.
17. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 169, 610-617.
18. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 56, 29-36.
19. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
20. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994). Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 151, 1234-1236.
21. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine : from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
22. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC (1996). Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biological Psychiatry 39, 213-215.
23. Meltzer H, Kostakaglu E, Lee M (2000). Response. Negative symptoms redux. Neuropsychopharmacology 22, 662-664.
24. Meltzer HY (1995). Clozapine: is another view valid? American Journal of Psychiatry 152, 821-825.
25. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychological Reports 10, 799-812.
26. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B (1999). Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry 156, 145-147.
27. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004a). Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. International Journal of Neuropsychopharmacology 7, 1-8.
28. Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY (1997a). Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Research 69, 113-121.
29. Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY (1997b). Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biological Psychiatry 41, 560-566.
30. Sumiyoshi T, Roy A, Anil AE, Jayathilake K, Ertugrul A, Meltzer HY (2004b). A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. Journal of Clinical Psychopharmacology 24, 345-348.
31. Sumiyoshi T, Roy A, Jayathilake K, Meltzer HY (2004c). The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. Journal of Clinical Psychopharmacology 24, 452-454.
32. Sumiyoshi T, Roy A, Kim CH, Jayathilake K, Lee MA, Sumiyoshi C, Meltzer HY (2004d). Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology (Berlin) 177, 79-83.
33. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 44, 1081-1089.
34. Tsai GE, Yang P, Chung L-C, Tsai I-C, Tsai C-W, Coyle JT (1999). D-Serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry 156, 1822-1825.
35. Waters Associates (1984). Pica-Tag Amino Acid Analysis System. Manual No. 88140. Milford, MA: Water Associates Publication Department.